Temodar

DRUG6 trials

Sponsors

Dana-Farber Cancer Institute, University of California, San Francisco, M.D. Anderson Cancer Center, Abramson Cancer Center at Penn Medicine, Duke University

Conditions

Advanced MelanomaEfficacy and SafetyGlioblastoma MultiformeGliosarcomaMelanomaMetastatic MelanomaNeuroendocrine Tumor

Phase 1

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

CompletedNCT00527761

M.D. Anderson Cancer CenterMetastatic Melanoma

Start: 2004-08-31End: 2007-11-30Updated: 2012-07-30

Study of Temzolomide and Gleevec in Advanced Melanoma

TerminatedNCT00667953

Abramson Cancer Center at Penn MedicineAdvanced Melanoma, Melanoma

Start: 2003-01-31End: 2011-03-09Updated: 2023-03-30

Phase 2

Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

CompletedNCT00165230

Dana-Farber Cancer InstituteNeuroendocrine Tumor

Start: 2002-05-31End: 2006-07-31Target: 32Updated: 2009-04-28

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

CompletedNCT00187486

University of California, San FranciscoGlioblastoma Multiforme, Gliosarcoma

Start: 2004-08-31End: 2011-03-31Updated: 2017-09-05

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

TerminatedNCT01186406

Duke UniversityGlioblastoma Multiforme, Gliosarcoma

Start: 2011-04-30End: 2014-06-16Updated: 2019-02-15

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

CompletedNCT03660761

Rongjie TaoEfficacy and Safety

Start: 2016-03-03End: 2018-01-06Updated: 2019-04-16